Breaking News Instant updates and real-time market news.

AXGT

Axovant

$1.45

0.02 (1.40%)

, HEAR

Turtle Beach

$11.96

-0.05 (-0.42%)

08:45
03/22/19
03/22
08:45
03/22/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Axovant Sciences (AXGT) 61.17% +39.14, Turtle Beach (HEAR) 90.82% +2.17, Village Farms International (VFF) 40.82% +0.68, Viking Therapeutics (VKTX) 4.37% +0.62, Tilray (TLRY) 49.64% +0.21, Energous (WATT) 42.28% +0.06, Baozun (BZUN) 6.16% +0.04, Canopy Growth (CGC) 11.67% +0.03, Hecla Mining (HL) 0.71% +0.03, and ProShares UltraShort Lehman 20 plus Year Treasury (TBT) 4.06% +0.02.

AXGT

Axovant

$1.45

0.02 (1.40%)

HEAR

Turtle Beach

$11.96

-0.05 (-0.42%)

VFF

Village Farms

$17.49

1.55 (9.72%)

VKTX

Viking Therapeutics

$9.29

1.02 (12.33%)

TLRY

Tilray

$70.18

-0.45 (-0.64%)

WATT

Energous

$6.19

0.39 (6.72%)

BZUN

Baozun

$37.96

1.15 (3.12%)

CGC

Canopy Growth

$46.05

-0.75 (-1.60%)

HL

Hecla Mining

$2.46

(0.00%)

TBT

ProShares UltraShort 20+ yr Trsry

$34.10

-0.14 (-0.41%)

  • 04

    Apr

AXGT Axovant
$1.45

0.02 (1.40%)

03/11/19
JMPS
03/11/19
NO CHANGE
Target $8
JMPS
Outperform
Axovant price target raised to $8 from $6 at JMP Securities
Following this morning's announcement of positive results from its AXO-Lenti-PD and AXO-AAV-GM2 programs, Axovant Sciences CEO provided additional color at a competitor conference which support the "compelling results," JMP Securities analyst Jason Butler tells investors in a research note. The analyst believes Axovant has assembled over the past 12 months a "differentiated and diversified" portfolio of gene therapy candidates. The AXO-Lenti-PD results demonstrated large improvements in motor function and reductions in dyskinesia, while the AXO-AAV-GM2 results showed a "clean" safety profile and demonstrated an "impressive" increase in Hex A enzyme activity, says Butler. He reiterates an Outperform rating on Axovant and raised his price target for the shares to $8 from $6. The stock in afternoon trading is up 31c, or 21%, to $1.79.
02/15/19
GUGG
02/15/19
INITIATION
Target $7
GUGG
Buy
Axovant initiated with a Buy at Guggenheim
Guggenheim analyst Whitney Ijem started Axovant with a Buy rating and $7.00 price target, stating that she likes the company's diversified approach in CNS gene therapy and sees "reason for optimism" ahead of initial data from two pipeline programs in March.
03/11/19
CHDN
03/11/19
UPGRADE
CHDN
Buy
Axovant upgraded to Buy from Neutral at Chardan
HEAR Turtle Beach
$11.96

-0.05 (-0.42%)

03/15/19
DADA
03/15/19
NO CHANGE
Target $23
DADA
Buy
Turtle Beach price target lowered to $23 from $26 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Turtle Beach to $23 from $26, saying that while its Q1 guidance and the pending acquisition of Roccat aimed to expand its product line were encouraging, its FY19 earnings outlook was disappointing. Excluding the $20M-$24M in revenue contribution from Roccat, the analyst sees the management's $220M-$224M outlook implying a 22%-24% decline, which is worse than his expected 10% slowdown and the initial consensus calling for a 15% slide. Forte is calling the outlook as overly conservative however and keeps his Buy rating on Turtle Beach given its "accelerating refresh cycle and more freemium title releases such as Apex Legends."
03/15/19
LSCM
03/15/19
NO CHANGE
Target $20
LSCM
Buy
Turtle Beach price target lowered to $20 from $40 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Turtle Beach to $20 from $40 after the company's fiscal 2019 guidance came in below expectations. While the revenue guidance midpoint of $244M was in line with consensus, ~$22M of that revenue is expected to come from the Roccat acquisition, Argento tells investors in a research note. The analyst, however, keeps a Buy rating on Turtle Beach.
02/07/19
LSCM
02/07/19
NO CHANGE
LSCM
Turtle Beach releases better-than-expected Q4 preannouncement, says Lake Street
Lake Street analyst Mark Argento maintained a Buy rating and $40 price target on Turtle Beach, after the company's Q4 preannouncement was "significantly ahead" of both consensus estimates and the company's guidance. The analyst noted that Turtle Beach's market share expanded in FY18, that the company generated significant free cash flow in FY18, and that the company is expecting strong gross margin in Q4 and for FY18. Argento believes Turtle Beach's FY19 will be closer to FY18 than FY17, given the company's expansion and larger installed base of hardware.
03/12/19
DADA
03/12/19
NO CHANGE
Target $26
DADA
Buy
Turtle Beach 'attractive at current levels', says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $26 price target on Turtle Beach ahead of its Q4 earnings this week, saying the company's pre-announcement last month was encouraging and its valuation at 10% free-cash flow yield is "attractive". The analyst contends that while lapping the strong 2018 performance driven by Fortnite popularity is a "tall order" for Turtle Beach, a contraction in its headset cycle refresh from 24 months to 18 months could yield upside to his projections.
VFF Village Farms
$17.49

1.55 (9.72%)

VKTX Viking Therapeutics
$9.29

1.02 (12.33%)

02/22/19
LEER
02/22/19
INITIATION
Target $10
LEER
Market Perform
Viking Therapeutics initiated with a Market Perform at SVB Leerink
SVB Leerink analyst Pasha Sarraf initiated Viking Therapeutics with a Market Perform rating and $10 price target, telling investors in a research note that Viking is positioning VK2809, a hepatic prodrug, thyroid receptor beta-selective agonist for NASH, as it pursues an IND with the GI division, to start Phase 2b trials this year. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
02/12/19
WBLR
02/12/19
NO CHANGE
WBLR
Viking could emerge as 'prime' buyout target for Gilead, says William Blair
Given Gilead Sciences' (GILD) leadership position in liver diseases and the significant resources that the company has devoted in the development of nonalcoholic steatohepatitis, last night's clinical setback "will likely reinvigorate" the company's willingness to augment its NASH pipeline, William Blair analyst Andy Hsieh tells investors in a research note. The analyst believes Gilead's Phase 3 failure could have a positive read-through to Viking Therapeutics (VKTX), which he notes is one of the only two beta-selective thyroid hormone receptor agonists in clinical testing. Viking's VK2809 demonstrated highly competitive data in reducing liver fat while maintaining a benign tolerability profile, Hsieh contends. Pending positive results from the company's Phase IIb study involving biopsy-confirmed NASH patients, he believes Viking Therapeutics "could emerge as a prime M&A target." The analyst keeps an Outperform rating on the shares. Viking in premarket trading is up 7% to $8.71.
01/17/19
RILY
01/17/19
NO CHANGE
Target $16
RILY
Buy
Viking selloff on Citron's Ligand report overdone, says B. Riley FBR
B. Riley FBR analyst Mayank Mamtani views the selloff yesterday in shares of Viking Therapeutics (VKTX) after Citron Research published a short report on Ligand Pharmaceuticals (LGND), the company's largest shareholder, as overdone. Interestingly, Ligand values Viking at a 10 times higher valuation than current trading levels, Mamtani tells investors in a research note. The analyst, whose firm does not cover Ligand, believes the report supports his thesis of Viking being an undervalued nonalcoholic steatohepatitis story. Additionally, competitor Lipocine's (LPCN) fat reduction data this morning, "while surprisingly positive," fell short of meeting/exceeding the 10.6% absolute fat reduction data reported from Viking in a Phase IIa study of early NASH patients, says Mamtani. He believes Viking Therapeutics maintains its "best in class status" and reiterates a Buy rating on the shares with a $16 price target. The stock in atfernoon trading is up 4%, or 35c, to $8.35.
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TLRY Tilray
$70.18

-0.45 (-0.64%)

03/19/19
PIPR
03/19/19
NO CHANGE
Target $90
PIPR
Overweight
Piper maintains Overweight rating, $90 target on Tilray after Q4 results
After Tilray reported a Q4 EBITDA loss of ($17.8M), Piper Jaffray analyst Michael Lavery says he does not expect positive earnings in near-term, as the company will remain in investment mode to drive growth. The Canadian market may become profitable as it ramps up, contends the analyst, but he does not expect positive total company EBITDA over the next five-to-seven quarters. However, Lavery expects strong industry growth long-term, and believes Tilray is well positioned to be one of several likely winners. He maintains an Overweight rating on the shares with a $90 price target.
03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/08/19
JEFF
03/08/19
INITIATION
Target $61
JEFF
Underperform
Tilray falls after Jefferies starts with Underperform rating, $61 target
Shares of Tilray (TLRY) are moving lower after Jefferies analyst Owen Bennett initiated coverage of the shares with an Underperform rating and $61 price target. Underperform is Jefferies' equivalent of a sell rating. Shares of Tilray are down 4%, or $2.97, to $66.75 in premarket trading. Bennett's 10-year discounted cash flow-driven valuation suggests the stock is "too expensive for its outlook." As a company wanting to be a global leader, the names that Tilray needs to be compared to are Canopy Growth (CGC) and Aurora Cannabis (ACB), Bennett tells investors in a research note. However, Tilray's Canada medical share is not in the top four and recent consumer feedback is "not inspiring," adds the analyst. Further, he believes the company's approach to recreational "does not appear as well thought through" and that its "optionality" in the U.S. is "less impressive." As such, Bennett struggles to justify Tilray's current valuation.
WATT Energous
$6.19

0.39 (6.72%)

08/02/18
ROTH
08/02/18
NO CHANGE
Target $24.5
ROTH
Buy
Energous price target lowered to $24.50 from $45.80 at Roth Capital
Roth Capital analyst William Gibson lowered his price target for Energous to $24.50 from $45.80 following quarterly results. The analyst reiterates a Buy rating on the shares.
10/31/18
LTCO
10/31/18
DOWNGRADE
Target $8
LTCO
Neutral
Energous downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Jon Hickman downgraded Energous to Neutral and lowered his price target for the shares to $8 from $24. The analyst says that while the company's market potential remains intact, its revenue ramp "remains elusive." He remains confident that Energous is on track to achieve "meaningful" product revenues in 2019 and become a notable participant in the wireless charging market. However, Hickman now anticipates a more modest revenue ramp through 2019 as customers "go through the necessary design integration and regulatory approvals." Energous is a leader in the wireless charging space, but the longer time to significant revenues requires a more modest valuation outlook, Hickman tells investors in a research note following Energous' Q3 results.
10/31/18
ROTH
10/31/18
NO CHANGE
Target $24.5
ROTH
Buy
Energous Tier 1 strategic partner progressed to product engineering, says Roth Capital
Roth Capital analyst William Gibson notes that Energous's (WATT) Tier One strategic partner has progressed from technology development to actual product engineering, and a minimal number of products are likely to be commercially available this Christmas. To date, three customers have announced WattUp-enabled commercial products, including SK Telesis Delight, Gokhale Method and Qubercomm Technologies, he notes, adding that a reference design transmitter is also available from Integrated Device (IDTI). Although Gibson does not anticipate large unit sales from initial early adopters, these companies pave the way for faster regulatory approval for future products. He expects the small form factor markets to be significant revenue contributors in 2019. The analyst reiterates a Buy rating and $24.50 price target on Energous shares
BZUN Baozun
$37.96

1.15 (3.12%)

10/11/18
LYON
10/11/18
UPGRADE
LYON
Buy
Baozun upgraded to Buy from Outperform at CLSA
CLSA analyst Man Ho Lam upgraded Baozun to Buy ahead of Q3 results citing the recent pullback in shares.
10/11/18
THCP
10/11/18
NO CHANGE
THCP
Baozun likely to be conservative with guidance, says TH Data Capital
TH Data Capital analyst Tian Hou believes Baozun added 10 GMV partners and 8 brand partners in Q3 and expects the company's net revenue growth to be in line with the consensus view and largely inline with the mid-point of company view. Given the slower pace of Chinese economic growth, Hou believes Baozun, along with many other Chinese companies, will take a conservative approach toward its guidance, he tells investors.
CGC Canopy Growth
$46.05

-0.75 (-1.60%)

03/05/19
JEFF
03/05/19
NO CHANGE
JEFF
Hedge funds building short thesis on Canopy Growth, says Jefferies
In a research note summarizing early feedback from investors on his cannabis initiations last week, Jefferies analyst Owen Bennett says hedge funds appear to be building a short thesis on Canopy Growth (CGC). The thesis focuses on harvesting concerns, which in Q2 came in at 15,217kg and then 7,556kg in Q3, Bennett tells investors in a research note. He points out that Canopy has attributed the reduction to rotation timing between harvests. The "short view is it could be due to crop failure due to scaling up too quickly," the analyst contends. With this in mind, he believes Canopy Growth's Q4 results will be very closely watched. Bennett has a Hold rating on Canopy Growth.
03/05/19
COWN
03/05/19
INITIATION
COWN
Outperform
Cowen starts Aurora at Outperform, replaces Canopy as top pick
Cowen analyst Vivien Azer initiated coverage of Aurora Cannabis (ACB) with an Outperform rating and C$14 price target. Aurora is "uniquely positioned" to drive leadership in both market share and profitability with the Canadian adult use market in the "early innings," Azer tells investors in a research note. Her analysis pegs Aurora's market share at an "impressive" 20% to date and shows the company has the number two position by in-stock SKU. Azer designated Aurora Cannabis as her Top Pick in cannabis, replacing Canopy Growth (CGC). Given that Canopy currently trades at 18 times estimated fiscal 2030 revenue estimates, Aurora's trading multiple "is defensible," says the analyst.
HL Hecla Mining
$2.46

(0.00%)

01/15/19
ADAM
01/15/19
DOWNGRADE
ADAM
Hold
Hecla Mining downgraded to Hold from Buy at Canaccord
02/28/19
RILY
02/28/19
DOWNGRADE
Target $3
RILY
Neutral
Hecla Mining downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Adam Graf downgraded Hecla Mining to Neutral after taking over coverage from Lucas Pipes. The analyst has a $3 price target for the shares. He says Hecla's upcoming refinancing is keeping him on the sidelines.
01/17/19
RBCM
01/17/19
DOWNGRADE
Target $2.75
RBCM
Underperform
Hecla Mining cut to Underperform at RBC Capital on challenging operating outlook
As noted earlier, RBC Capital analyst Mark Mihaljevic downgraded Hecla Mining to Underperform from Sector Perform and lowered his price target to $2.75 from $3.25. The analyst cites the company's "challenging operating outlook" given the slow turnaround of its recently purchased Nevada operations. Mihaljevic is also concerned with Hecla's limited free cash flow and elevated financial leverage after it was able to generate only $12M in cash flow while ending the year with $27M in cash in 2018.
01/17/19
RBCM
01/17/19
DOWNGRADE
RBCM
Underperform
Hecla Mining downgraded to Underperform from Sector Perform at RBC Capital
TBT ProShares UltraShort 20+ yr Trsry
$34.10

-0.14 (-0.41%)

TODAY'S FREE FLY STORIES

SPOT

Spotify

$121.52

0.795 (0.66%)

13:25
09/23/19
09/23
13:25
09/23/19
13:25
Options
Spotify call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

AMD

AMD

$30.62

0.58 (1.93%)

13:24
09/23/19
09/23
13:24
09/23/19
13:24
Hot Stocks
AMD up 2% to $30.64 in afternoon trading »

At time of writing, AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/23/19
09/23
13:17
09/23/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/23/19
09/23
13:16
09/23/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/23/19
09/23
13:15
09/23/19
13:15
General news
Fed's Bullard said the Committee might opt to ease again »

Fed's Bullard said…

NVO

Novo Nordisk

$53.06

0.11 (0.21%)

13:05
09/23/19
09/23
13:05
09/23/19
13:05
Options
Novo Nordisk call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

IPHI

Inphi

$60.80

-2.69 (-4.24%)

, AMZN

Amazon.com

$1,789.48

-4.16 (-0.23%)

12:59
09/23/19
09/23
12:59
09/23/19
12:59
Recommendations
Inphi drops after Northland sees 'large cut' to Amazon 400G rollout plans »

Northland analyst Tim…

IPHI

Inphi

$60.80

-2.69 (-4.24%)

AMZN

Amazon.com

$1,789.48

-4.16 (-0.23%)

CSCO

Cisco

$49.59

(0.00%)

ACIA

Acacia Communications

$64.58

-0.04 (-0.06%)

LITE

Lumentum

$57.55

-1.28 (-2.18%)

NPTN

NeoPhotonics

$6.24

-0.03 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 26

    Sep

  • 10

    Oct

  • 27

    Oct

  • 13

    Nov

HUYA

Huya

$27.43

-0.47 (-1.68%)

12:55
09/23/19
09/23
12:55
09/23/19
12:55
Options
HUYA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLY

Annaly Capital

$9.02

0.06 (0.67%)

12:45
09/23/19
09/23
12:45
09/23/19
12:45
Options
Annaly Capital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRT

Trio-Tech

$3.79

0.08 (2.16%)

12:45
09/23/19
09/23
12:45
09/23/19
12:45
Hot Stocks
Breaking Hot Stocks news story on Trio-Tech »

Trio Tech International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
09/23/19
09/23
12:45
09/23/19
12:45
General news
Breaking General news story  »

St. Louis Federal Reserve…

IPHI

Inphi

$61.21

-2.28 (-3.59%)

12:43
09/23/19
09/23
12:43
09/23/19
12:43
Recommendations
Inphi analyst commentary  »

Inphi mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRT

Trio-Tech

$3.79

0.08 (2.16%)

12:41
09/23/19
09/23
12:41
09/23/19
12:41
Earnings
Trio-Tech reports Q4 EPS 12c vs. 17c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$377.77

-1.56 (-0.41%)

, ERJ

Embraer

$18.27

-0.46 (-2.46%)

12:37
09/23/19
09/23
12:37
09/23/19
12:37
Periodicals
Boeing bid of Embraer unit faces EU antitrust probe, Reuters reports »

The European Union's…

BA

Boeing

$377.77

-1.56 (-0.41%)

ERJ

Embraer

$18.27

-0.46 (-2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

OBAS

Optibase

$12.50

(0.00%)

12:36
09/23/19
09/23
12:36
09/23/19
12:36
Hot Stocks
Optibase: Appeal filed against court decision to deny motion to approve claim »

Optibase announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$114.56

-1.6 (-1.38%)

12:35
09/23/19
09/23
12:35
09/23/19
12:35
Options
Eli Lilly put volume heavy and directionally bearish »

Bearish flow noted in Eli…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 23

    Oct

AEM

Agnico Eagle

$59.23

1.02 (1.75%)

12:32
09/23/19
09/23
12:32
09/23/19
12:32
Conference/Events
Agnico Eagle management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 24

    Oct

TRT

Trio-Tech

$3.79

0.08 (2.16%)

12:26
09/23/19
09/23
12:26
09/23/19
12:26
Hot Stocks
Breaking Hot Stocks news story on Trio-Tech »

Trio Tech International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDE

Coeur Mining

$5.65

0.38 (7.21%)

12:25
09/23/19
09/23
12:25
09/23/19
12:25
Options
Coeur Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:20
09/23/19
09/23
12:20
09/23/19
12:20
General news
A Firming Pattern for U.S. Producer Sentiment: »

A Firming Pattern for…

PSTV

Plus Therapeutics

$11.00

3.04 (38.19%)

12:17
09/23/19
09/23
12:17
09/23/19
12:17
Syndicate
Plus Therapeutics 3M unit offering priced at $5 per unit »

Plus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/23/19
09/23
12:17
09/23/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/23/19
09/23
12:16
09/23/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYSI

BeyondSpring

$18.78

0.92 (5.15%)

12:15
09/23/19
09/23
12:15
09/23/19
12:15
Hot Stocks
BeyondSpring to present Pegfilgrastim data at ESMO Congress »

BeyondSpring announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

AZO

AutoZone

$1,160.25

-0.13 (-0.01%)

, KMX

CarMax

$86.63

1.95 (2.30%)

12:15
09/23/19
09/23
12:15
09/23/19
12:15
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AZO

AutoZone

$1,160.25

-0.13 (-0.01%)

KMX

CarMax

$86.63

1.95 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.